TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06409637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4 regimen
Description: FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study.
Study: NCT04704102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET)
Description: A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain (SCS)
Description: It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham SCS
Description: SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
Study: NCT05479812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Investigation Product in combination with approved therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Investigation Product in combination with approved therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Investigation Product in combination with approved therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Investigation Product in combination with approved therapy
Study: NCT06571682

Intervention type: DEVICE
Intervention: Target Controlled Infusion
Description: TCI (Target Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.

Intervention type: DRUG
Intervention: Inhalation anesthetic
Description: In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
Study: NCT04531579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid Solution
Description: Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
Study: NCT06571812

Intervention type: DEVICE
Intervention: TSX
Description: Treatment of tooth loss with TSX dental implants
Study: NCT06263803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening, classic physical therapy
Description: Participants will listen to the music pieces Pachabel Canon in D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes), free from external sounds (max 70 dB through headphones).

Intervention type: OTHER
Group type: OTHER
Intervention: Music listening, classic physical therapy
Description: Participants will listen to the music pieces Pachabel Canon in D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes), free from external sounds (max 70 dB through headphones).
Study: NCT05760313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule; oral
Study: NCT05797376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5mg
Description: patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
Study: NCT06297447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE4Adults - pain science education
Description: Is formerly described under arm descriptions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Is formerly described under arm descriptions
Study: NCT06015438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Participants will perform a minimum of one exercise from each of the targeted muscle groups at a frequency of every other day, for a total of 3-4 days a week of exercise with a rest day. The entire strengthening exercise routine should take approximately 25-30 minutes to perform, including rest periods. Each muscle grouping of exercises is designed to progress from minimal muscle effort required to moderate to maximal effort. Participants will use a video to perform the exercises as well as a handout with specific instructions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short Exercise Program
Description: Participants in this group will attend one in-person visit expected to last about 60 minutes. The clinic visit will consist of standard of care procedures and tests for individuals with mild-to-severe HS .
Study: NCT06386107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombin Generation Assay (TGA)
Description: Hemostasis is a complex process in which genetic or environmental conditions can cause shifts either towards pro-thrombotic states resulting in thrombosis, or towards pro-hemorrhagic states resulting in uncontrolled bleeding. Tests to assess a more global hemostatic profile, such as the TGA, have appeared as a more reliable alternative to assess the real hemostatic capacity of an individual. TGA is a global dynamic assay simultaneously and continuously measuring thrombin generation. It monitors the cleavage of a fluorigenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.
Study: NCT05478837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-H3.3K27M TCR-expressing T-cells
Description: Given IV
Study: NCT06558175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT)
Description: Patients will be assigned to treatment doses using the TITE-CRM model.
Study: NCT06571227

Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction
Description: Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
Study: NCT06565676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread with whey protein powder added
Description: Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread with whey protein powder added
Description: Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread with whey protein powder added
Description: Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread with whey protein powder added
Description: Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.
Study: NCT05322733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: 150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
Study: NCT05704803

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: IN Vitro
Description: In vitro diagnostic test for COVID-19 using anterior nasal swabs.
Study: NCT06213480

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic Group
Description: WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
Study: NCT05750784

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee arthroplasty using the active robotic surgical system
Description: Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee arthroplasty using the active robotic surgical system
Description: Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
Study: NCT05322733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
Study: NCT04741971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics group
Description: Will give Probiotics with Vitamin D3 one drop per day for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-probiotics group
Description: Will give Vitamin D3 five drops per day for 90 days
Study: NCT06179095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.
Study: NCT05541718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki
Description: Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
Study: NCT05786326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group 1
Description: Insertion of fully covered self-expanding metallic stents with multi-holes (FCSEMS- MH) Biliary stent HANAROSTENT® CCC (M.I.Tech Co., Ltd, pyeongtaek, Korea) in a biliary tree through endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia by expertise in patients with malignant biliary obstruction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: group 2
Description: Insertion of partially covered self-expanding metallic stents HANAROSTENT® Biliary (NCN) in the biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: group 3
Description: Insertion of uncovered self-expanding metallic stents (Biliary stent HANAROSTENT® NNN) (M.I.Tech Co., Ltd. Pyeongtaek, Korea) in a biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
Study: NCT05634200

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
Study: NCT05336695

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR Imaging
Description: PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-FBP8
Description: Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
Study: NCT05935085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANB032
Description: BTLA agonist antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANB032
Description: BTLA agonist antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANB032
Description: BTLA agonist antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06541951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: During this phase of the stepped wedge design, agencies offering prenatal and postnatal care will follow their standard procedures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scale-up implementation approach
Description: An implementation approach for scaling up bundled equity-focused maternal health safety guidelines in community care settings county-wide, co-developed with partners. It may involve implementation approaches such as training, facilitation, learning collaboratives, coalitions, and other activities.
Study: NCT05425121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core stability exercises
Description: The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercises
Description: The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
Study: NCT06317272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIBH using ABC technique
Description: Deep breath inspiration hold (DIBH) using Active Breathing Control (ABC) technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIBH using VC technique
Description: Deep breath inspiration hold (DIBH) using Voluntary Coaching (VC) technique
Study: NCT05425121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Description: EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
Study: NCT04958096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Therapeutic Deep Brain Stimulation
Description: DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Therapeutic Deep Brain Stimulation
Description: DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortical Stimulation for PFC
Description: Patients enrolled in this study will have a second pair of leads placed in the prefrontal cortex (PFC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortical Stimulation for ACC
Description: Patients enrolled in this study will have a second pair of leads placed in the anterior cingulate cortex (ACC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
Study: NCT05888064

Intervention type: DIAGNOSTIC_TEST
Intervention: diffusion MRI sequences
Description: Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
Study: NCT04932772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Exercises
Description: Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Exercises
Description: Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
Study: NCT05880524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase Alfa
Description: Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline Solution
Description: Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
Study: NCT06259019

Intervention type: DEVICE
Group type: OTHER
Intervention: Liquid Biopsy System (LBS)
Description: Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
Study: NCT06547320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Less Intervention
Description: A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the amount of food eaten.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Slower Intervention
Description: A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the rate of eating.
Study: NCT00916916

Intervention type: OTHER
Intervention: Blood draw
Description: A blood draw will occur to take 10cc of blood to measure lanreotide levels.